Shares dropped more than 16% from their IPO price amid worries about possible U.S. delisting of Chinese businesses. BeiGene, led by American billionaire entrepreneur John Oyler, raised the equivalent ... ( read original story ...)
Biotech BeiGene slides in Shanghai after US$3.5 billion STAR debut
Cancer treatment specialist BeiGene Ltd plunged 16.4per cent on its Shanghai debut on Wednesday after raising US$3.5 billion, hit by concerns over its valuation amid potential U.S. sanctions on ... ( read original story ...)
End of an era for Shanghai restaurant icon
After two decades, pioneering Australian restaurateur Michelle Garnaut has decided to close the doors of her iconic M on the Bund restaurant in Shanghai. ( read original story ...)
Hong Kong shares lead losses as investors digest Chinese economic data; biotech firm BeiGene debuts in Shanghai
Asia-Pacific markets were mostly down Wednesday, with Chinese markets declining as investors digested key Chinese economic data. Meanwhile, Chinese biotech firm BeiGene made its debut in Shanghai. ( read original story ...)
Regulator approves China Mobile Shanghai listing
China Mobile received approval from the nation's financial regulator to raise billions of dollars by listing in Shanghai. ( read original story ...)
Shanghai Quartet Moves to Back to China as Chamber Music Takes Off in Country
The Shanghai Quartet, an internationally known string quartet formed almost four decades ago, has decided to move back to China after being based in the United States for the past 30 years, as chamber ... ( read original story ...)
BeiGene’s Shanghai stock debut flops as excessive premium, running losses keep investors at bay
The biggest IPO on Star Market flopped after BeiGene shares slumped by as much as 19 per cent on the first day of trading in Shanghai. Concerns about US delisting and steep declines in its Hong Kong ... ( read original story ...)